Insulin Treatment in Patients With Type 1 Diabetes Induces Upregulation of Regulatory T-Cell Markers in Peripheral Blood Mononuclear Cells Stimulated With Insulin In Vitro
Open Access
- 1 December 2006
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 55 (12), 3446-3454
- https://doi.org/10.2337/db06-0132
Abstract
Patients with type 1 diabetes are treated with daily injections of human insulin, an autoantigen expressed in thymus. Natural CD4+CD25high regulatory T-cells are derived from thymus, and accordingly human insulin–specific regulatory T-cells should exist. We had a chance to study peripheral blood mononuclear cells (PBMCs) from children with type 1 diabetes both before and after starting insulin treatment, and thus we could analyze the effects of insulin treatment on regulatory T-cells in children with type 1 diabetes. PBMCs were stimulated for 72 h with bovine/human insulin. The mRNA expression of regulatory T-cell markers (transforming growth factor-β, Foxp3, cytotoxic T-lymphocyte antigen-4 [CTLA-4], and inducible co-stimulator [ICOS]) or cytokines (γ-interferon [IFN-γ], interleukin [IL]-5, IL-4) was measured by quantitative RT-PCR. The secretion of IFN-γ, IL-2, IL-4, IL-5, and IL-10 was also studied. The expression of Foxp3, CTLA-4, and ICOS mRNAs in PBMCs stimulated with bovine or human insulin was higher in patients on insulin treatment than in patients studied before starting insulin treatment. The insulin-induced Foxp3 protein expression in CD4+CD25high cells was detectable in flow cytometry. No differences were seen in cytokine activation between the patient groups. Insulin stimulation in vitro induced increased expression of regulatory T-cell markers, Foxp3, CTLA-4, and ICOS only in patients treated with insulin, suggesting that treatment with human insulin activates insulin-specific regulatory T-cells in children with newly diagnosed type 1 diabetes. This effect of the exogenous autoantigen could explain the difficulties to detect in vitro T-cell proliferation responses to insulin in newly diagnosed patients. Furthermore, autoantigen treatment–induced activation of regulatory T-cells may contribute to the clinical remission of the disease.Keywords
This publication has 48 references indexed in Scilit:
- Effects of interleukin 4 on CD25+CD4+ regulatory T cell functionJournal of Autoimmunity, 2005
- THE B7 FAMILY REVISITEDAnnual Review of Immunology, 2005
- Detection of Autoreactive T Cells in Type 1 Diabetes Using Coded Autoantigens and an Immunoglobulin‐Free Cytokine ELISPOT Assay: Report from the Fourth Immunology of Diabetes Society T Cell WorkshopAnnals of the New York Academy of Sciences, 2004
- CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic LesionThe Journal of Experimental Medicine, 2004
- Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cellsJournal of Autoimmunity, 2003
- Type 1 Diabetes MellitusPediatrics in Review, 2003
- Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group.Journal of Clinical Investigation, 1998
- Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseasesImmunology Today, 1995
- Cellular immunity to human insulin in individuals at high risk for the development of Type I diabetes mellitusJournal of Autoimmunity, 1990
- Insulin-binding antibody: Reaction differences with bovine and porcine insulinsDiabetologia, 1978